Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Unknown 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × abivertinib × Clear all
NCT03574402 2022-12-06

TRUMP

Guangdong Association of Clinical Trials

Phase 2 Unknown
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03300115 2019-02-19

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 2 Unknown
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡